Article info
PDFTherapeutics
Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis
Citation
Rosiglitazone increased heart failure but did not differ from metformin plus sulphonylurea for other CV outcomes at interim analysis
Publication history
- First published December 6, 2007.
Online issue publication
October 25, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
2007 by the BMJ Publishing Group for Evidence-Based Medicine and by the ACP for portions reproduced from ACP Journal Club